I've only just got round to reading the XPAND Trial data article by Ascherman et al published in December 2016, and I really am impressed by the results which make for a very viable product.
With the main benefits being mean time to full expansion, patient comfort/control and reduced visits, what are the cost differences to the hospitals and also the consumer? Newer tech is going to cost more I guess my question is in relation to the cost-benefit ratio. Will the product be patient or insurance funded?
I've only just got round to reading the XPAND Trial data article...
Add AXP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.824M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $4.303K | 2.151M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 40085905 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 91807222 | 63 |
View Market Depth
| Last trade - 10.57am 04/12/2024 (20 minute delay) ? |
| AXP (ASX) Chart |
